Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

US9163093B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Jijie Gu · Shrewsbury, US
• Dominic J. Ambrosi · Shrewsbury, US
• Susan E. Lappe · Riverwoods, US
• Yingchun Li · 安丰镇, CN
• Jonathan A. Hickson · Lake Villa, US
• Deanna L. Haasch · Grayslake, US
• Supriya Gupta · Sunnyvale, US
• Ravi Chari · Norwich, US
• Camellia Zamiri · Fremont, US
• Louie Naumovski · Los Altos, US
• Xianhua Cao · Hawthorn Woods, US

Key dates

• Filing date: Oct 31, 2013
• Grant date: Oct 20, 2015
• Expiry date: Oct 31, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.